<code id='A90D592F7B'></code><style id='A90D592F7B'></style>
    • <acronym id='A90D592F7B'></acronym>
      <center id='A90D592F7B'><center id='A90D592F7B'><tfoot id='A90D592F7B'></tfoot></center><abbr id='A90D592F7B'><dir id='A90D592F7B'><tfoot id='A90D592F7B'></tfoot><noframes id='A90D592F7B'>

    • <optgroup id='A90D592F7B'><strike id='A90D592F7B'><sup id='A90D592F7B'></sup></strike><code id='A90D592F7B'></code></optgroup>
        1. <b id='A90D592F7B'><label id='A90D592F7B'><select id='A90D592F7B'><dt id='A90D592F7B'><span id='A90D592F7B'></span></dt></select></label></b><u id='A90D592F7B'></u>
          <i id='A90D592F7B'><strike id='A90D592F7B'><tt id='A90D592F7B'><pre id='A90D592F7B'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:17
          Sammy Kimball for STAT

          Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen’s boardroom scandal has roiled a company that was supposed to be entering a new era.

          advertisement

          For more on what we cover, here’s the Laronde story; here’s the latest on Biogen; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          leisure time

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead
          In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

          InsitroCEOandfounderDaphneKollerNeilsonBarnard/GettyImagesforTheNewYorkTimesSANFRANCISCO—Ittookonlya

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

          5:06RepublicanpresidentialcandidateFloridaGov.RonDeSantisspeaksduringafundraisingeventforU.S.Rep.Ash